Compare Quest Diagnostics Inc (DGX) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI China ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while iShares MSCI China ETF trades at $52.55 (market cap $5.94B). The key difference: Quest Diagnostics Inc is far larger — about 4.3× iShares MSCI China ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares MSCI China ETF for 63 Days on average.
| DGX | MCHI | |
|---|---|---|
Market Cap | $25.48B | $5.94B |
Volume | 941,866 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $65.59 |
52-Week Low | $173.49 | $50.48 |
Typical Hold Time | 56 Days | 63 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
MCHI trades at $51.36, down 0.54% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption, though some indicators like the 12-day RSI suggest potential oversold conditions. Recent news highlights trade tensions and policy uncertainty ahead of key US-China meetings.
While MCHI trades at historical discounts to US indices according to Seeking Alpha (2026-08-10), the bearish technical setup and China's macroeconomic risks create near-term pressure. Potential catalysts include progress in trade talks and corporate profit growth, but investors face significant exposure to China's regulatory environment and global trade dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
